SWX:ROPPharmaceuticals
Roche Holding (SWX:ROP) Wins FDA Clearance, Is It Fully Priced?
Roche Holding (SWX:ROP) has seen fresh attention after the U.S. FDA granted 510(k) clearance for its cobas BV/CV molecular assay. This clearance expands the company’s diagnostics menu in vaginal and broader sexual health testing.
See our latest analysis for Roche Holding.
Alongside the new cobas BV/CV assay, Roche Holding’s share price is at CHF364.70, with a 30-day share price return of 9.92% and a 1-year total shareholder return of 51.19%, indicating that momentum has been building despite...